Cardiovascular Effects of L-158,809, a New Angiotensin Type 1 Receptor Antagonist, Assessed Using the Halothane-Anesthetized In Vivo Canine Model.
-
- Yoneyama Masahiko
- Department of Pharmacology, Yamanashi Medical University
-
- Sugiyama Atsushi
- Department of Pharmacology, Yamanashi Medical University
-
- Yoshida Hiroshi
- Department of Pharmacology, Yamanashi Medical University
-
- Satoh Yoshioki
- Department of Pharmacology, Yamanashi Medical University
-
- Hashimoto Keitaro
- Department of Pharmacology, Yamanashi Medical University
この論文をさがす
抄録
L-158,809 is a new angiotensin II type 1 receptor antagonist. We simultaneously assessed its antagonistic potency and cardiovascular effects with the halothane-anesthetized in vivo canine model (n = 5). L-158,809 was intravenously infused over 10 min at escalating doses of 0.03, 0.3 and 3 mg/kg. Angiotensin II (0.1 μg/kg, i.v.)-induced vasopressor and negative inotropic responses were significantly suppressed from the low dose L-158,809. Meanwhile, L-158,809 did not affect any of the cardiovascular parameters except that QTc was slightly shortened after the high dose administration. These results support the previous in vitro knowledge that L-158,809 is a highly selective angiotensin II receptor antagonist.
収録刊行物
-
- Jpn.J.Pharmacol.
-
Jpn.J.Pharmacol. 89 (2), 192-196, 2002
公益社団法人 日本薬理学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679262649088
-
- NII論文ID
- 10008684253
-
- NII書誌ID
- AA00691188
-
- COI
- 1:STN:280:DC%2BD38znsFOmtA%3D%3D
-
- ISSN
- 13473506
- 00215198
-
- NDL書誌ID
- 6262145
-
- PubMed
- 12120764
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可